Skip to main content
Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. — Investor Relations & Filings

Ticker · CANF ISIN · IL0010944739 LEI · 549300ZLRH6GSBOHFZ59 TA Manufacturing
Open in API
Filings indexed 2,169 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country IL Israel
Listing TA CANF

About Can-Fite BioPharma Ltd.

https://www.canfite.com/

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.

Recent filings

Filing Released Lang Actions
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market2
Regulatory Filings Classification · 21% confidence The document is a Form 6-K filing by a foreign private issuer to furnish a press release (Exhibit 99.1) about a peer-reviewed scientific publication. It is a routine regulatory submission under the Securities Exchange Act for material corporate news rather than a financial report, earnings release, or specific transaction notice. It does not contain actual financial statements or request shareholder action, nor does it fit other narrow categories. Therefore, it is best classified under the general “Regulatory Filings” category (RNS).
2026-05-18 English
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market2
Report Publication Announcement Classification · 87% confidence The text is a short MAGNA/ISA announcement (2,045 characters) stating the scheduled publication time for a report and that the report is attached (ea029123101-6k_canfiteEDGAR1_Bannerless_isa.pdf). It contains no substantive financial statements or management commentary – it merely announces the timing and attachment of a report. Under the “menu vs meal” rule, this is a Report Publication Announcement, not the report itself.
2026-05-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2026-05-18 English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
Regulatory Filings
2026-05-13 English
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Regulatory Filings Classification · 78% confidence The document is a Form 6-K filed by Can-Fite BioPharma Ltd. attaching a press release about clinical trial progress. It is not a financial report (10-K, IR), not earnings (ER), not management change (MANG), not a dividend, not an investor presentation, and contains no officer certification alone. It is a general regulatory filing/announcement of a press release, best classified under Regulatory Filings (RNS).
2026-05-13 English
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Report Publication Announcement Classification · 90% confidence The document is a brief regulatory announcement by Can-Fite Biopharma to the Tel Aviv Stock Exchange under Regulation 5 (Periodic and Immediate Reports of Foreign Corporation). It states that a report is "attached hereto" on the company’s Phase 2a pancreatic cancer data and that the publication is scheduled for 13/05/2026 at 14:00. It contains no substantive financial or operational data itself, merely notification that a report is available. Per the “menu vs meal” rule, this is a Report Publication Announcement rather than the report itself.
2026-05-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.